S458
Clinical - Gynaecological
ESTRO 2026
13 Department of Biomedical Science, Humanitas University, Milano, Italy.
floor rehabilitation during the treatment. Within the EORTC QLQ CX-24, lymphedema showed a worsening trend at T3 compared with T1 ( β 8.9, p 0.098, 95% CI [-1.70; 19.60]) and was related to the total dose delivered on the pelvis ( > 50 Gy(RBE)). Compared to radical HT, patients receiving HT as a post- RT/CT boost experienced worsening in social functioning ( β -16.51 p = 0.015, 95% CI [– 29.67; –3.35]), with a trend toward worsening insomnia ( β 14.83 p = 0.058, 95% CI [–0.50; 30.16]) and an higher sexual worries ( β 26.02, p 0.05, 95% CI [-0.02; 52.06]). Conclusion: Overall, even at radical doses or when combined with RT/CT in selected gynaecological cancers, HRQoL remained largely stable, with only modest trends suggesting symptom fluctuations and potential treatment-related differences. The emerging patterns might inform future hypothesis-driven analyses, particularly regarding sexual functioning domains and treatment-related differences in sexual concerns. References: 1.Barcellini, A., Charalampopoulou, A., Franzetti, J. et al. Carbon ion radiotherapy in gynaecological oncology: where we are and where we are headed. Health Technol. 14, 859–866 (2024)2.Kirchheiner K, Pötter R, Nout RA, et al. Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidity- Applied in the EMBRACE Study. Int J Radiat Oncol Biol Phys. 2020;106(2):300-309. Keywords: QOL; Particle Beam Radiotherapy; Rare Tumors
14 Radiotherapy Unit, Ospedale di Circolo Fondazione Macchi, Varese, Italy. 15 Research
Center for Reproductive Medicine, Gynaecological Endocrinology and Menopause Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Purpose/Objective: This pilot study investigates health-related quality of life (HRQoL) in patients with rare or radioresistant gynecological malignancies treated with hadrontherapy (HT), administered either as definitive upfront therapy or as a boost following radical conventional radiochemotherapy (RT/CT). Material/Methods: HRQoL was evaluated using the EORTC QLQ- C30 and EORTC QLQ-CX24 questionnaires at baseline (T1), at the last follow-up (T3), and, when available, at intermediate timepoints (T2). Longitudinal changes and associations with clinical variables were examined using uni- and multivariate linear regression models (two-tailed tests, significance threshold p<0.05). Results: Thirty-four consecutive patients were enrolled, including newly diagnosed cases (73.5%) and RT-naïve patients with oligoprogression (26.5%). The mean age was 60.4 years (SD 14.26) and mucosal melanoma was the most common subtype(26.5%). The total prescribed dose ranged from 40 to 68.8 Gy(RBE) for upfront HT and 16.6 to 38.4 Gy(RBE) for boost treatments. Across the EORTC QLQ C30 and CX-24 instruments, no statistically significant global changes in HRQoL were observed over time. However, several clinically relevant trends emerged. Financial difficulties displayed a numerical reduction at later timepoints (from 25.48 at T1 to 12.12 at T3) and social functioning increased slightly from T1 to T3 (73.53 to 77.94). Active sexual functioning improved at T2 compared with T1 ( β 7.88, p 0.09, 95%CI [- 1.26; 17.03]) in patients performing pelvic
Made with FlippingBook - Share PDF online